Raffaella Lucchini

🔗Two fantastic days in beautiful Sorrento 😍, enjoying art and learning new things. Outstanding presentation by @tompowles1 on systemic therapy💊🧬🧪in metastatic #bladdercancer and new SOC. Thanks to ASTELLAS

Here the official position of AIRO, Italian Association of Radiotherapy and Clinical Oncology in regard to IRRADIaTE, the Italian Registry of RT-Associated Urological Treatment. @EurUrolOncol . In press. euoncology.europeanurology.com/article/S2588-… thanks to @GiuliaMarvaso84 & @CiroFranzese1

📌 Stereotactic Body Radiation Therapy⚡️for High-Risk Prostate 🌰Cancer ➡️ our systematic review mdpi.com/3713722 #mdpiuro via @MDPIOpenAccess

🚨 Prostate cancer care has changed fast. Here’s the 2025 snapshot. The new Lancet Seminar lays out how prostate cancer management has transformed across the disease spectrum 🌍🧬 🔍 Early disease Active surveillance is the default for low-risk tumors, avoiding overtreatment while maintaining excellent outcomes. MRI-first pathways improve detection of clinically significant cancer. ⚖️ Localized to high-risk Surgery and modern radiotherapy offer equivalent cancer control. Hypofractionation and SBRT shorten treatment without compromising efficacy. High-risk disease needs multimodality care. 🚀 Metastatic hormone-sensitive ADT alone is no longer enough. Doublet or triplet therapy with ARPIs ± docetaxel is now standard, with prostate RT benefiting low-volume disease. 🎯 mCRPC era Treatment is biology-driven: PARP inhibitors for HRR alterations, Lu-177 PSMA radioligand therapy after ARPI and taxanes, cabazitaxel preferred over ARPI sequencing. 🧠 Big takeaway Sequencing, patient selection, toxicity, and shared decision-making matter as much as drug choice. 📖 Valérie Fonteyne et al. Lancet 2025 A must-read, practice-defining review for every GU oncologist 🔖 #OncoTwitter #MedTwitter #ProstateCancer #GUOncology @TheLancet @myESMO @OncoAlert @ASCO

The STONE Trial is officially active. With over 20 Italian centers involved, the study aims to strengthen the evidence on role of SBRT for unresectable primary renal tumors, a safe and effective ablative treatment #SBRT #radiotherapy #kidney @GiuliaMarvaso84 @GiulioFrancoli1

@drdavidpalma @DrOlsonOncology @DrAlisonAllan @DrCorreaRO Congratulations! 👏🏻

Some great news! @DrOlsonOncology ‘s SABR-COMET-3 completed accrual today!! 330 randomized with 1-3 Mets, primary endpoint OS. Biomarker studies led by @DrAlisonAllan and @DrCorreaRO. Readout maybe in 2027, with COMET10 likely in 2026.

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: Meta-Analysis jamanetwork.com/journals/jamao… Meta-analysis of over 10,000 patients from 13 randomized trials found that the survival benefit of androgen deprivation therapy (ADT) combined with radiotherapy is highly dependent on both treatment duration and patient risk profile, with diminishing returns beyond roughly 9–12 months and increasing non–cancer-related mortality with prolonged therapy. Optimal duration varied by disease severity—shorter or no ADT for lower-risk intermediate disease, longer courses for higher-risk groups—highlighting that extended therapy is not universally beneficial. Because longer ADT improves cancer-specific outcomes but also increases other-cause mortality, the study emphasizes tailoring duration based on individual risk, comorbidities, life expectancy, and patient preference rather than applying uniform treatment lengths. #ProstateCancer @NicholasZaorsky @yilun_sun @StatMatt9 @DrHowardSandler @drjefstathiou @Soum_Roy_RadOnc @DrPaulNguyen @jeshoag @PBarataMD @angela_jia_ @MSteinbergMD @AmarUKishan @DrSpratticus @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

#AIRO2025 ⚡️💊🧬 Three days to share ideas, meet colleagues and friends 🫂, and have fun🍸🎊 A special thank you to all AIRO GU group colleagues for these two fantastic years!🩵

@Fefe_Ferrario Late as always…even on social media 😅 but always thrilled to share! ✨ Amazing UroOnco days at #EMUC25 in stunning Prague 🇨🇿 — brilliant sessions, great people, and lots of take-home messages 💡 Heading back energized⚡️and with an extra souvenir: a cold 🤒

4 days at #EMUC2025 in Prague! @CiroFranzese1 @Fefe_Ferrario @PaulSargos

So proud to share mid-term results of our POPART trial on prostate bed SBRT — core of my thesis and a project I deeply believe in ✨ Alongside #SCIMITAR & #SHORTER, another step towards the 5fx revolution! 💥 Forever🙏🏼@StAr_MCM74 50days free access⬇️ authors.elsevier.com/c/1lYbQcA0-MUS1

A week at @DCPTprotons ☢️🇩🇰: a great experience. Thanks to the prof @m_hoyer12 and all the staff for their hospitality! #protontherapy

#ESTRO25 You’ve been amazing ✨ ~2️⃣nd year in a row on stage with the #POPART trial ~🌍 Global connections with inspiring minds ~🏅 Top 5% abstract — couldn’t be prouder! 🙏🏼 Infinite thanks to my mentor & colleagues. Here’s to science, passion&teamwork! #RadOnc #prostatecancer

Today in Castelfranco for the lII edition of Advanced Uro-Oncology Days. My presentation about #MDT in oligoM+ #urothelialcancer. Many compliments to @mat_sepu , @therealmarcodoc, and to scientific committee of the event!

Joining forces against kidney cancer! Published a new international multicenter study on SBRT for renal cell carcinoma SBRT is a valuable option with: ✅ 96% local control at 5 years ✅ Good preservation of renal function ✅ Acceptable toxicity profile with only 1% of G ≥3

Our latest research on oligorecurrent kidney cancer patients treated with upfront SBRT. Key predictive factors that contribute to long-term disease control, offering valuable insights for personalized treatment strategies and prospective trials. lnkd.in/eJEhgk_6

STRILL: Phase I trial of stereotactic reirradiation of lung metastases previously treated with SBRT ..unsurprisingly, 50/5# reirradiation yields higher local control without notable toxicity. Nice collaboration with @HumanitasMilano @MartaScorsetti mdpi.com/2079-9721/12/7…

🎬 our paper on 1️⃣-shot⚡️RT for UIR and HR PCa is finally out on @IJROBP 👏kudos to the authors for the team effort! #ABRUPT @CChissotti @Fefe_Ferrario @Raffa_Lucchini @MariaBelmonte95 @riccardo_ray @valefacc22 @PanizzaDenis redjournal.org/article/S0360-…

Stereotactic body radiation therapy for prostate cancer after surgical treatment of prostatic obstruction: Impact on urinary morbidity ⁦@Achard_Verane⁩ ⁦@VedangMurthy⁩ ⁦@docpriyamvada⁩ ctro.science/article/S2405-…

@FabArcidiacono8 @HumanitasMilano @MartaScorsetti Thanks ☺️

@Raffa_Lucchini @HumanitasMilano @MartaScorsetti Congrats and good luck!

I’m excited to start a new experience… #RadOnc at @HumanitasMilano ‼️ Thanks to Prof @MartaScorsetti for this opportunity!